Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Fate Therapeutics Inc shares valued at $104,881 were purchased by Wolchko J Scott on Mar 06 ’25. At $0.93 per share, Wolchko J Scott acquired 113,178 shares.
Also, Bressi Jerome Charles sold 5,980 shares, netting a total of over 9,269 in proceeds. Following the sale of shares at $1.55 each, the insider now holds 270,203 shares.
Before that, TAHL CINDY had sold 5,654 shares from its account. In a trade valued at $8,764, the insider traded Fate Therapeutics Inc shares for $1.55 each. Upon closing the transaction, the insider’s holdings decreased to 5,654 shares, worth approximately $0.39 million.
As published in a research note from BofA Securities on November 18, 2024, Fate Therapeutics Inc [FATE] has been rated up from an Underperform to a Neutral. Analysts at Piper Sandler upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in mid June. Earlier on January 24, 2023, H.C. Wainwright downgraded its rating. Their new recommendation was “a Neutral” for FATE stock which previously was a “a Buy”.
Analyzing FATE Stock Performance
On last trading session,, Fate Therapeutics Inc [NASDAQ: FATE] plunged -0.85% to $1.16. The stock’s lowest price that day was $1.12, but it reached a high of $1.195 in the same session. During the last five days, there has been a drop of approximately -3.33%. Over the course of the year, Fate Therapeutics Inc shares have dropped approximately -69.15%. Shares of the company reached a 52-week high of $1.9900 on 01/06/25 and a 52-week low of $0.6611 on 04/04/25.
Support And Resistance Levels for Fate Therapeutics Inc (FATE)
According to the 24-hour chart, there is a support level at 1.1217, which, if violated, would cause prices to drop to 1.0833. In the upper region, resistance lies at 1.1967. The next price resistance is at 1.2333. RSI (Relative Strength Index) is 44.52 on the 14-day chart, showing neutral technical sentiment.
Is Fate Therapeutics Inc subject to short interest?
Stocks of Fate Therapeutics Inc saw a sharp steep in short interest on 2025-05-30 dropping by -2.29 million shares to 11.05 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 13.34 million shares. A decline of -20.77% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.24 of the overall float, the days-to-cover ratio (short ratio) decline to 6.24.
Which companies own the most shares of Fate Therapeutics Inc (FATE)?
In terms of Fate Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 3 in the next 12 months, up nearly 156.41% from the previous closing price of $1.17. Analysts anticipate Fate Therapeutics Inc stock to reach 3 by 2025, with the lowest price target being 3. In spite of this, 8 analysts ranked Fate Therapeutics Inc stock as Buy at the end of 2025. On January 06, 2023, Wedbush assigned a price target of “a Neutral” to the stock and downgraded coverage with a $7.
